Rakovina Therapeutics Valuation

Is RKV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RKV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RKV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RKV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RKV?

Key metric: As RKV is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RKV. This is calculated by dividing RKV's market cap by their current book value.
What is RKV's PB Ratio?
PB Ratio	1.4x
Book	CA$3.81m
Market Cap	CA$5.42m

RKV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-2.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does RKV's PB Ratio compare to its peers?

The above table shows the PB ratio for RKV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.1x
QPT Quest PharmaTech	0.3x	n/a	CA$6.8m
GTTX GeneTether Therapeutics	3.1x	n/a	CA$1.5m
TELO Telo Genomics	16.4x	n/a	CA$8.2m
MPH Medicure	0.5x	n/a	CA$9.4m
RKV Rakovina Therapeutics	1.4x	n/a	CA$5.4m

Price-To-Book vs Peers: RKV is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (5.1x).

Price to Book Ratio vs Industry

How does RKV's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
QPT Quest PharmaTech	0.3x	n/a	US$4.81m
CURE.X Biocure Technology	0.2x	n/a	US$222.42k

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: RKV is good value based on its Price-To-Book Ratio (1.4x) compared to the Canadian Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is RKV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RKV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RKV's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$707.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.05

-13.9%

-64.7%

Decibel Cannabis

CA$27.7m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

CA$0.06

-7.7%

-50.0%

Cresco Labs

CA$581.1m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.69

-25.6%